MCO
67
3
NTAP
58
3
CTAS
36
8
KSS
36
2
CHRW
53
2
MS
64
3
CVS
27
2
GME
61
2
MCD
52
3
OI
23
3
ROST
60
3
QRVO
16
-6
CCL
68
6
AA
27
5
APH
53
3
AKAM
50
2
EXR
42
5
MA
60
5
RCL
74
5
MU
42
14
MCO
67
3
NTAP
58
3
CTAS
36
8
KSS
36
2
CHRW
53
2
MS
64
3
CVS
27
2
GME
61
2
MCD
52
3
OI
23
3
ROST
60
3
QRVO
16
-6
CCL
68
6
AA
27
5
APH
53
3
AKAM
50
2
EXR
42
5
MA
60
5
RCL
74
5
MU
42
14
Financhill
Back

Standard BioTools 10K Form

Buy
56

LAB
Standard BioTools

Last Price:
$2.00
Seasonality Move:
15.27%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive LAB News And Ratings

See the #1 stock for the next 7 days that we like better than LAB

LAB Financial Statistics

Sales & Book Value

Annual Sales: $106.3M
Cash Flow: $-30.1M
Price / Cash Flow: 0
Annual Sales: $1.31
Price / Book: 1.52

Profitability

EPS (TTM): -0.71000
Net Income (TTM): $-124.6M
Gross Margin: $50.5M
Return on Equity: -48.03%
Return on Assets: -22.01%

Standard BioTools Earnings Forecast

Key Standard BioTools Financial Ratios

  • The Gross Profit Margin over the past 18 years for LAB is 47.44%.
  • The Selling, General & Administrative Expenses for LAB have been equal to 82.32% of Gross Profit Margin.
  • The Research & Development expenses have been 24.40% of Revenue.
  • The Interest Expense is -6.12% of Operating Income.
  • The Net Earning history of LAB is -70.21% of Total Revenues.
  • Per Share Earnings over the last 18 years have been positive in 10 years.

Standard BioTools Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Life Sciences Tools & Services
Sector: Health Care
Current Symbol: LAB
Website: standardbio.com

Debt

Debt-to-Equity Ratio: 0.11
Current Ratio: 3.76
Quick Ratio: 3.33

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

LAB Technical Analysis vs Fundamental Analysis

Buy
56
Standard BioTools (LAB) is a Buy

Is Standard BioTools a Buy or a Sell?

  • Standard BioTools stock is rated a Buy
    The current Standard BioTools [LAB] share price is $2.00. The Score for LAB is 56, which is 12% above its historic median score of 50, and infers lower risk than normal.